Ultra-high sensitivity, expanded flexibility, increased stability and robustness - the new Nexera X2 UHPLC system targets routine analysis and applications in highly regulated environments demanding complex system setups.
Nexera X2 – X-ceptional insights
Ultra-high sensitivity, expanded flexibility, increased stability and robustness - the new Nexera X2 UHPLC system targets routine analysis and applications in highly regulated environments demanding complex system setups.
System flexibility
The system flexibility is based on software features which control multiple gradients in a single system. This enables automated solvent blending on each pump in a binary gradient setup. The software has been adapted to meet the requirements for use in highly regulated environments.
Stability
Stability in gradient use has been improved by pump side modifications. Furthermore, design changes on inlet valve and degassing unit minimize air bubbles passing through the flow line and reduce their negative effects on stability and performance. For addressing specific appli-cations, additional micro reactor based mixing devices can be selected accordingly. A newly designed low volume quaternary option reduces the system volume to meet UHPLC needs while enabling a better inter-system method transfer.
Sensitivity
The new SPD-M30A photodiode array detector is perfectly suited ultra-high sensitive applica-tions using a capillary cell with low dispersion. Total reflection and a high energy deuterium lamp guarantee a low noise level. A novel temperature control principle decreases baseline drift and offers improved reliability even under changing environment conditions. Together with ultra-high speed data acquisition, software features which maximize resolution on the PDA while enabling peak deconvolution squeeze the maximum information out of a single analysis.
For more information please visit www.shimadzu.eu.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.